Castle Biosciences Showcases Advances in Skin Cancer Testing at 2025 Dermatology Conference

Castle Biosciences Advances Skin Cancer Management at Upcoming Conference

Castle Biosciences, Inc., a Texas-based company specializing in innovative testing for skin cancers, prepares to present significant findings from its dermatologic gene expression profile (GEP) tests at the upcoming 2025 Winter Clinical Dermatology Conference in Waikoloa Village, Hawaii, from February 14-19. The company's vice president of research and development, Dr. Rebecca Critchley-Thorne, emphasizes Castle's ongoing commitment to enhancing patient care through advanced testing solutions tailored for skin cancer management. The conference serves as a platform for Castle to showcase several key presentations that underline its pivotal role in the dermatological field.

One major highlight is the "DecisionDx®-Melanoma" presentation, led by Dr. J. Michael Guenther. This poster discusses the i31-SLNB test's efficacy in identifying melanoma patients with less than a 5% risk of sentinel lymph node positivity. This information is crucial for refining patient management strategies, as it enables healthcare providers to make more informed decisions regarding treatment plans and surveillance for at-risk patients. By integrating this test into clinical practice, healthcare professionals can enhance their approach to melanoma diagnosis and treatment, ultimately leading to improved patient outcomes.

Another important presentation at the conference is the "DecisionDx®-SCC," which focuses on a 40-gene expression profile test aimed at identifying immunosuppressed patients with cutaneous squamous cell carcinoma (cSCC) who are at a heightened risk of metastasis. This study, led by Karina Brito, BS, highlights potential implications for adjuvant radiation therapy, showcasing how targeted testing can inform therapeutic decisions. Additionally, the "MyPath® Melanoma" presentation by Brooke H. Russell, Ph.D., discusses strategies to improve access to prognostic GEP testing for invasive melanoma through RNA-based testing. Together, these presentations reinforce Castle Biosciences’ commitment to advancing the understanding and treatment of skin cancers through rigorous clinical research and innovative testing solutions.

Castle Biosciences has built a strong foundation in skin cancer diagnostics, supported by over 50 peer-reviewed studies and analysis of more than 10,000 patient samples. Its DecisionDx-Melanoma test is linked to enhanced patient survival outcomes, solidifying the company's reputation in the dermatological landscape. Attendees at the conference can engage with Castle's findings at their booth in the exhibit hall, where further information about their presentations and innovative testing solutions will be available.

As Castle Biosciences continues to push the boundaries of skin cancer management, its presence at this prominent conference highlights the importance of ongoing research and innovation in improving patient care.